KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Revenue (2016 - 2025)

Vertex Pharmaceuticals has reported Revenue over the past 17 years, most recently at $3.2 billion for Q4 2025.

  • Quarterly results put Revenue at $3.2 billion for Q4 2025, up 9.55% from a year ago — trailing twelve months through Dec 2025 was $12.0 billion (up 8.9% YoY), and the annual figure for FY2025 was $12.0 billion, up 8.9%.
  • Revenue for Q4 2025 was $3.2 billion at Vertex Pharmaceuticals, up from $3.1 billion in the prior quarter.
  • Over the last five years, Revenue for VRTX hit a ceiling of $3.2 billion in Q4 2025 and a floor of $1.7 billion in Q1 2021.
  • Median Revenue over the past 5 years was $2.5 billion (2023), compared with a mean of $2.5 billion.
  • Biggest five-year swings in Revenue: grew 28.98% in 2021 and later increased 2.96% in 2025.
  • Vertex Pharmaceuticals' Revenue stood at $2.1 billion in 2021, then grew by 11.1% to $2.3 billion in 2022, then rose by 9.34% to $2.5 billion in 2023, then grew by 15.66% to $2.9 billion in 2024, then grew by 9.55% to $3.2 billion in 2025.
  • The last three reported values for Revenue were $3.2 billion (Q4 2025), $3.1 billion (Q3 2025), and $3.0 billion (Q2 2025) per Business Quant data.